Windtree Therapeutics “announced that on April 2, 2024 the Company entered into an asset purchase agreement with Varian Biopharmaceuticals to acquire certain of its assets, including a proprietary atypical protein kinase C iota inhibitor. The Company also completed a $1.5 million convertible note bridge financing.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
- WINT Earnings this Week: How Will it Perform?
- Windtree Therapeutics CFO Resigns Amid Cost-Cutting Measures
- Windtree Therapeutics files to sell 608,272 shares of common stock for holders
